The objective of our laboratory is to understand the molecular determinants of cellular survival that allow tumor cells to escape programmed cell death (apoptosis) when they are exposed to chemotherapy or irradiation. Identifying specific molecules that promote survival will provide new, attractive targets for the development of compounds that abrogate survival signals and enhance therapeutic effectiveness. Cellular survival is determined by factors both within the cell and outside the cell, including the contribution of extracellular influences such as soluble growth factors and extracellular matrix molecules. Both growth factors and extracellular matrix molecules stimulate survival through activation of enzymatic pathways within the cell that involve proteins that either add phosphate to downstream substrates (kinase) or remove phosphate (phosphatases). The best described survival pathways depend on activity from kinases such as P13K, Akt, PKC, and MAPK, that become activated when they themselves are phosphorylated. Activation can occur after binding of extracellular growth factors to their cognate receptors, or in the case of some tumor cells, activation is independent of extracellular growth factors and is constitutive. Recently, we have described a role for three signaling pathways that contribute to the survival and therapeutic resistance of lung cancer cells: the PI3K/Akt pathway, the MEK/ERK pathway, and pathways involving isoforms of PKC. Because lung cancer cells appear to be most dependent upon the Akt pathway, we have focused in the last year on this pathway. Four separate studies from our group have highlighted the importance of the PI3K/Akt/mTOR pathway. First, tobacco components activate the pathway in two types of normal human lung epithelial cells, which causes an Akt-dependent, partially transformed phenotype. Second, lung lesions induced by a tobacco carcinogen, NNK, are characterized by progressive activation of the Akt pathway. Third, most lung cancer cells have constitutively activated Akt, which promotes resistance to chemotherapy and radiation. Fourth, Akt activation has prognostic significance for patients with NSCLC. We found that Akt activation is selective for NSCLC tumors vs. surrounding normal lung tissue and confers a poor prognosis for all NSCLC patients, but especially for those with early stage disease. This observation is highly important because most asymptomatic patients who are diagnosed through screening will have early stage disease.

Agency
National Institute of Health (NIH)
Institute
Division of Clinical Sciences - NCI (NCI)
Type
Intramural Research (Z01)
Project #
1Z01SC010292-08
Application #
7331446
Study Section
(MOB)
Project Start
Project End
Budget Start
Budget End
Support Year
8
Fiscal Year
2006
Total Cost
Indirect Cost
Name
Clinical Sciences
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Wang, Yun; Digiovanna, John J; Stern, Jere B et al. (2009) Evidence of ultraviolet type mutations in xeroderma pigmentosum melanomas. Proc Natl Acad Sci U S A 106:6279-84
Granville, Courtney A; Memmott, Regan M; Balogh, Andria et al. (2009) A central role for Foxp3+ regulatory T cells in K-Ras-driven lung tumorigenesis. PLoS One 4:e5061
LoPiccolo, Jaclyn; Blumenthal, Gideon M; Bernstein, Wendy B et al. (2008) Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat 11:32-50
Tsurutani, Junji; Steinberg, Seth M; Ballas, Marc et al. (2007) Prognostic significance of clinical factors and Akt activation in patients with bronchioloalveolar carcinoma. Lung Cancer 55:115-21
LoPiccolo, Jaclyn; Granville, Courtney A; Gills, Joell J et al. (2007) Targeting Akt in cancer therapy. Anticancer Drugs 18:861-74
Lopiccolo, Jaclyn; Ballas, Marc S; Dennis, Phillip A (2007) PTEN hamartomatous tumor syndromes (PHTS): rare syndromes with great relevance to common cancers and targeted drug development. Crit Rev Oncol Hematol 63:203-14
Lipkowitz, Stanley; Dennis, Phillip A (2007) PPARgamma agonists follow an unknown TRAIL in lung cancer. Cancer Biol Ther 6:107-9
Granville, Courtney A; Warfel, Noel; Tsurutani, Junji et al. (2007) Identification of a highly effective rapamycin schedule that markedly reduces the size, multiplicity, and phenotypic progression of tobacco carcinogen-induced murine lung tumors. Clin Cancer Res 13:2281-9
Tsurutani, Junji; Fukuoka, Junya; Tsurutani, Hiroko et al. (2006) Evaluation of two phosphorylation sites improves the prognostic significance of Akt activation in non-small-cell lung cancer tumors. J Clin Oncol 24:306-14
Fiala, Emerich S; Sohn, Ock Soon; Wang, Chung-Xiou et al. (2005) Induction of preneoplastic lung lesions in guinea pigs by cigarette smoke inhalation and their exacerbation by high dietary levels of vitamins C and E. Carcinogenesis 26:605-12

Showing the most recent 10 out of 22 publications